Complete financial analysis of Avis Budget Group, Inc. (CAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avis Budget Group, Inc., a leading company in the Rental & Leasing Services industry within the Industrials sector.
You may be interested
- Xingfa Aluminium Holdings Limited (0098.HK) Income Statement Analysis – Financial Results
- Y. T. Realty Group Limited (0075.HK) Income Statement Analysis – Financial Results
- Visionox Technology Inc. (002387.SZ) Income Statement Analysis – Financial Results
- Stampede Drilling Inc. (SDI.V) Income Statement Analysis – Financial Results
- Freja eID Group AB (publ) (FREJA.ST) Income Statement Analysis – Financial Results
Avis Budget Group, Inc. (CAR)
About Avis Budget Group, Inc.
Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.01B | 11.99B | 9.31B | 5.40B | 9.17B | 9.12B | 8.85B | 8.66B | 8.50B | 8.49B | 7.94B | 7.36B | 5.90B | 5.19B | 5.13B | 5.98B | 6.03B | 5.69B | 18.24B | 19.79B | 18.19B | 14.09B | 8.95B | 3.93B | 5.40B | 5.28B | 5.31B | 2.35B | 1.42B | 1.04B | 875.00M | 738.90M | 641.30M | 450.80M | 365.00M | 268.60M | 195.30M | 138.30M | 84.20M |
| Cost of Revenue | 7.24B | 1.23B | 1.51B | 1.69B | 2.41B | 2.49B | 2.51B | 2.33B | 2.22B | 2.29B | 2.08B | 1.77B | 1.51B | 1.59B | 1.72B | 2.01B | 1.93B | 1.74B | 10.68B | 10.34B | 9.41B | 6.72B | 2.94B | 1.31B | 1.10B | 609.20M | -184.00M | -3.00M | -74.00M | -95.70M | -94.70M | -109.10M | -106.70M | -73.00M | 128.50M | 10.40M | 16.90M | 900.00K | 2.40M |
| Gross Profit | 4.77B | 10.76B | 7.80B | 3.72B | 6.77B | 6.63B | 6.34B | 6.33B | 6.28B | 6.21B | 5.86B | 5.59B | 4.39B | 3.59B | 3.41B | 3.97B | 4.10B | 3.95B | 7.55B | 9.45B | 8.78B | 7.37B | 6.01B | 2.62B | 4.31B | 4.67B | 5.50B | 2.35B | 1.49B | 1.14B | 969.70M | 848.00M | 748.00M | 523.80M | 236.50M | 258.20M | 178.40M | 137.40M | 81.80M |
| Gross Profit Ratio | 39.69% | 89.74% | 83.79% | 68.79% | 73.76% | 72.68% | 71.67% | 73.08% | 73.86% | 73.09% | 73.86% | 75.97% | 74.42% | 69.32% | 66.50% | 66.35% | 68.04% | 69.48% | 41.41% | 47.75% | 48.28% | 52.29% | 67.18% | 66.56% | 79.69% | 88.47% | 103.46% | 100.13% | 105.23% | 109.16% | 110.82% | 114.77% | 116.64% | 116.19% | 64.79% | 96.13% | 91.35% | 99.35% | 97.15% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.49B | 1.28B | 1.06B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 583.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 0.00 | 0.00 | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Selling & Marketing | -81.00M | 64.00M | 81.00M | 54.00M | 121.00M | 116.00M | 111.00M | 127.00M | 123.00M | 112.00M | 116.00M | 127.00M | 0.00 | -14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.71B | 2.01B | 1.76B | 1.39B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.41B | 1.35B | 1.15B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 569.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 1.99B | 1.20B | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Other Expenses | 0.00 | 5.51B | 4.53B | 3.54B | 4.95B | 4.90B | 4.75B | 4.61B | 4.50B | 4.43B | 4.23B | 3.95B | 3.12B | 2.71B | 2.73B | 3.24B | 3.12B | 2.99B | 1.57B | 3.06B | 3.01B | 2.56B | 2.30B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| Operating Expenses | 1.58B | 6.86B | 5.67B | 4.25B | 6.19B | 6.05B | 5.81B | 5.68B | 5.54B | 5.51B | 5.22B | 4.86B | 3.88B | 3.28B | 3.27B | 3.89B | 3.78B | 3.81B | 5.35B | 6.64B | 6.13B | 5.07B | 4.31B | 1.40B | 2.76B | 3.41B | 3.99B | 1.90B | 1.22B | 949.90M | 827.10M | 746.50M | 664.50M | 481.30M | 208.80M | 274.60M | 147.80M | 122.10M | 73.90M |
| Cost & Expenses | 8.82B | 8.09B | 7.18B | 5.93B | 8.59B | 8.55B | 8.31B | 8.02B | 7.76B | 7.80B | 7.30B | 6.63B | 5.39B | 4.87B | 4.98B | 5.90B | 5.70B | 5.55B | 16.03B | 16.97B | 15.54B | 11.79B | 7.25B | 2.72B | 3.85B | 4.02B | 3.81B | 1.90B | 1.14B | 854.20M | 732.40M | 637.40M | 557.80M | 408.30M | 337.30M | 285.00M | 164.70M | 123.00M | 76.30M |
| Interest Income | 0.00 | 1.00M | 1.00M | 12.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 296.00M | 250.00M | 218.00M | 231.00M | 178.00M | 188.00M | 188.00M | 203.00M | 194.00M | 209.00M | 228.00M | 268.00M | 219.00M | 162.00M | 153.00M | 129.00M | 127.00M | 236.00M | 1.34B | 251.00M | 797.00M | 1.27B | 1.84B | 401.00M | 3.93B | 1.46B | 2.36B | 340.80M | 8.70M | 0.00 | 0.00 | 2.10M | 60.80M | 11.00M | 15.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.45B | 2.81B | 2.48B | 2.56B | 3.14B | 2.23B | 2.21B | 2.13B | 163.00M | 2.02B | 128.00M | 109.00M | 95.00M | 90.00M | 96.00M | 1.73B | 1.65B | 1.47B | 1.29B | 3.20B | 3.46B | 2.72B | 2.17B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| EBITDA | 6.43B | 7.15B | 4.74B | 2.17B | 3.96B | 2.99B | 2.88B | 2.98B | 794.00M | 2.92B | 477.00M | 693.00M | 350.00M | 332.00M | 172.00M | 841.00M | 1.10B | 1.35B | 1.73B | 1.31B | 6.18B | 5.01B | 3.88B | 1.64B | 4.54B | 3.69B | 4.65B | 1.32B | 729.00M | 569.30M | 475.90M | 407.70M | 383.50M | 250.60M | 187.80M | 116.20M | 74.50M | 54.10M | 31.30M |
| EBITDA Ratio | 53.57% | 34.50% | 25.80% | -5.72% | 8.57% | 8.46% | 8.31% | 9.68% | 10.62% | 31.98% | 9.69% | 11.42% | 10.34% | 7.89% | 4.74% | 30.17% | 32.76% | 28.30% | 24.39% | 30.30% | 33.95% | 38.23% | 51.73% | 41.78% | 84.04% | 69.80% | 87.55% | 56.28% | 51.52% | 54.49% | 54.39% | 55.18% | 59.80% | 55.59% | 51.45% | 42.07% | 38.15% | 39.12% | 37.17% |
| Operating Income | 3.19B | 3.91B | 2.13B | -529.00M | 579.00M | 516.00M | 476.00M | 585.00M | 685.00M | 696.00M | 617.00M | 715.00M | 515.00M | 305.00M | 129.00M | 76.00M | 325.00M | 143.00M | 866.00M | 2.80B | 2.71B | 1.03B | 2.46B | 1.31B | 3.47B | 2.11B | 2.66B | 617.00M | 275.10M | 190.50M | 138.30M | 98.20M | 105.90M | 39.80M | 29.50M | -19.60M | 27.40M | 11.80M | 7.00M |
| Operating Income Ratio | 26.57% | 32.62% | 22.88% | -9.79% | 6.31% | 5.66% | 5.38% | 6.76% | 8.06% | 8.20% | 7.77% | 9.72% | 8.73% | 5.88% | 2.51% | 1.27% | 5.39% | 2.51% | 4.75% | 14.15% | 14.92% | 7.30% | 27.51% | 33.38% | 64.25% | 39.85% | 49.99% | 26.28% | 19.44% | 18.23% | 15.81% | 13.29% | 16.51% | 8.83% | 8.08% | -7.30% | 14.03% | 8.53% | 8.31% |
| Total Other Income/Expenses | -1.28B | -270.00M | -423.00M | -965.00M | -280.00M | -499.00M | -623.00M | -606.00M | -303.00M | -577.00M | -520.00M | -415.00M | -479.00M | -247.00M | -206.00M | -1.42B | -1.32B | -820.00M | -213.00M | 1.77B | -445.00M | -700.00M | -1.05B | -354.00M | -2.18B | -1.00B | -754.70M | -170.40M | -4.40M | 0.00 | -400.00K | -5.40M | -38.40M | -13.70M | -13.90M | 1.80M | 4.00M | 4.30M | -700.00K |
| Income Before Tax | 1.91B | 3.64B | 1.71B | -956.00M | 287.00M | 267.00M | 211.00M | 279.00M | 382.00M | 392.00M | 97.00M | 300.00M | 36.00M | 72.00M | -77.00M | -1.34B | -992.00M | -677.00M | 1.35B | 2.55B | 2.21B | 1.64B | 658.00M | 885.00M | -635.00M | 264.40M | 294.70M | 276.20M | 266.40M | 190.50M | 142.20M | 96.10M | 45.10M | 28.80M | 13.80M | -14.60M | 31.40M | 16.10M | 7.20M |
| Income Before Tax Ratio | 15.94% | 30.32% | 18.34% | -17.70% | 3.13% | 2.93% | 2.38% | 3.22% | 4.49% | 4.62% | 1.22% | 4.08% | 0.61% | 1.39% | -1.50% | -22.47% | -16.46% | -11.90% | 7.38% | 12.88% | 12.15% | 11.62% | 7.35% | 22.52% | -11.75% | 5.00% | 5.54% | 11.76% | 18.83% | 18.23% | 16.25% | 13.01% | 7.03% | 6.39% | 3.78% | -5.44% | 16.08% | 11.64% | 8.55% |
| Income Tax Expense | 279.00M | 880.00M | 425.00M | -272.00M | -15.00M | 102.00M | -150.00M | 116.00M | 69.00M | 147.00M | 81.00M | 10.00M | 65.00M | 18.00M | -30.00M | -219.00M | -45.00M | -226.00M | 474.00M | 728.00M | 745.00M | 556.00M | 235.00M | 309.00M | -406.00M | 104.50M | 239.30M | 112.10M | 103.00M | 72.90M | 54.80M | 37.30M | 20.00M | 11.30M | 5.70M | -3.30M | 14.00M | 7.40M | 4.40M |
| Net Income | 1.63B | 2.76B | 1.29B | -684.00M | 302.00M | 165.00M | 361.00M | 163.00M | 313.00M | 245.00M | 16.00M | 290.00M | -29.00M | 54.00M | -47.00M | -1.12B | -916.00M | -1.99B | 1.34B | 2.08B | 1.17B | 846.00M | 385.00M | 602.00M | -55.00M | 539.60M | 55.40M | 164.10M | 163.40M | 117.60M | 87.40M | 58.80M | 25.10M | 17.50M | 8.10M | -11.30M | 17.40M | 8.70M | 2.80M |
| Net Income Ratio | 13.59% | 23.04% | 13.80% | -12.66% | 3.29% | 1.81% | 4.08% | 1.88% | 3.68% | 2.89% | 0.20% | 3.94% | -0.49% | 1.04% | -0.92% | -18.81% | -15.20% | -35.05% | 7.35% | 10.52% | 6.44% | 6.01% | 4.30% | 15.32% | -1.02% | 10.21% | 1.04% | 6.99% | 11.55% | 11.26% | 9.99% | 7.96% | 3.91% | 3.88% | 2.22% | -4.21% | 8.91% | 6.29% | 3.33% |
| EPS | 42.61 | 58.44 | 19.80 | -9.70 | 4.02 | 2.08 | 4.32 | 1.78 | 3.02 | 2.32 | 0.15 | 2.72 | -0.28 | 0.53 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 20.29 | 11.50 | 7.57 | 4.20 | 8.40 | -0.73 | 6.40 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| EPS Diluted | 42.06 | 57.11 | 19.44 | -9.70 | 3.99 | 2.06 | 4.25 | 1.75 | 2.98 | 2.22 | 0.15 | 2.42 | -0.28 | 0.49 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 19.66 | 11.30 | 7.57 | 4.10 | 8.10 | -0.73 | 6.10 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| Weighted Avg Shares Out | 38.30M | 47.30M | 64.90M | 70.50M | 75.20M | 79.30M | 83.40M | 92.00M | 103.40M | 105.40M | 107.60M | 106.60M | 105.20M | 103.10M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 101.91M | 111.76M | 91.67M | 71.67M | 75.10M | 84.38M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
| Weighted Avg Shares Out (Dil) | 38.80M | 48.40M | 66.10M | 70.50M | 75.70M | 80.10M | 84.80M | 93.30M | 105.00M | 110.60M | 111.40M | 121.60M | 105.20M | 126.70M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 103.72M | 111.76M | 93.90M | 74.32M | 75.10M | 88.52M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
New Highs for Dow Transports: Top 3 Stocks Driving the Surge
The Dow Jones Transportation Average rose more than 8.4% in November to set a new high. Most components saw gains, with only two moving lower.
Clinical trials for HEMO-CAR-T: What's next? ICYMI
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr.Vladislav Sandler and non-executive director Peter Redmond talked with Proactive about key developments, including its EGM. Redmond explained the reasoning behind share consolidation, aimed at attracting institutional investors and enhancing the company's capital structure as it...
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR...
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company's Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash...
Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy
AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by November 2025 for top-ten F500IL dogs, with Energy Transfer as...
MOTORTREND NAMES MERCEDES-BENZ E-CLASS 2025 CAR OF THE YEAR
– Mercedes-Benz's elegant midsize luxury car has outdone its competitors to secure MotorTrend's Golden Calipers for the second time in five years – LOS ANGELES , Nov. 20, 2024 /PRNewswire/ -- MotorTrend Group , a Warner Bros. Discovery company, announced today...
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on...
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune...
Source: https://incomestatements.info
Category: Stock Reports